89BIO, INC stock forecast: up to 19.49 USD ETNB stock price prognosis
Forecast for Thu 16 Dec 2021 price
89BIO, INC stock price forecast for further price development up to 12.10% (time horizon: 1 day) and price target of 19.49 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) 89BIO, INC share price prediction for 2021-12-16 with daily closed price projections
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.
Summerized Form 10-K with GPT-2
There are currently no approved products for the treatment of NASH. BIO89-100 was well tolerated across the dose range in this trial. The primary endpoint is the reduction in fasting triglycerides from baseline. Topline data from ENTRIGUE are expected in the second half of 2021. NASH represents a large and rapidly growing problem in the United States and worldwide. In addition, it is estimated that 8% of patients with advanced fibrosis will develop HCC. NASH is a complex, multifaceted disease that doesn't just affect the liver. Disease Overview - SHTG We are also developing BIO89-100 for the treatment of SHTG. Some fish oils have also showed major increases in LDL-C (up to 45%). The problem is compounded further as insulin resistance develops. Figure 3 below shows the structure of BIO89-100. The ratiopharm Sublicense will continue until terminated in accordance with its terms. ratiopharm may terminate the ratiopharm Sublicense for certain material breaches by us. GlycoPEGylated FGF21 is specifically claimed. One U.S. application is pending in this family. The PCT Application for this family was filed on September 4, 2018 (PCT/IB2018/00112). This patent application is not published. Below is a summary of some of the risks we face. Our stock is a highly speculative investment. We may be unable to design and execute a clinical trial to support regulatory approval. 41 & We must attract and retain highly skilled employees in order to succeed. As a result, we may enter into additional license agreements in the future.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 35.19/100
Good financial position.
Historical view, profit is not growing.
Company revenue is not growing faster compared with the
Institutional ownership list is based on filling form information
89BIO, INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
On-Balance Volume information for 89BIO, INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for 89BIO, INC. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for 89BIO, INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for 89BIO, INC. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for 89BIO, INC. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for 89BIO, INC. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for 89BIO, INC. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio